| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/29/2007 | US7223849 For inhibiting neoplastic cell growth in a human or mouse |
| 05/29/2007 | US7223845 Which have one or more sulfated tyrosine residues and a glycan linked to the peptide, the glycan preferably including a sialyl Lewisx group or a sialyl Lewisa group; antiinflammatory, antithrombotic, antimetastatic compounds |
| 05/29/2007 | US7223837 Anticancer prodrugs, enhance enzymatic activation rates |
| 05/29/2007 | US7223798 treating inflammatory or autoimmune disorders and pulmonary or respiratory tract inflammation |
| 05/29/2007 | US7223797 New salts such as meldonium dihydrogen phosphate, meldonium hydrogen fumarate or meldonium orotate; nonhygroscopic and/or increased thermal stability and/or lasting action |
| 05/29/2007 | US7223796 Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use |
| 05/29/2007 | US7223795 Modified peptide derivatives and methods of use thereof |
| 05/29/2007 | US7223794 For example, 2-{[(1S)-2-amino-1-phenylethyl]oxy}-4-chloro-5-fluorobenzonitrile; use in treatment or prophylaxis of inflammatory diseases and CNS diseases |
| 05/29/2007 | US7223793 Excellent effects of reducing blood lipid level, inhibiting cholesterol metabolism-related enzymes |
| 05/29/2007 | US7223792 Cytotoxic annonaceous acetogenins from Annona muricata |
| 05/29/2007 | US7223791 Function regulator for retinoid relative receptor |
| 05/29/2007 | US7223790 Dimeric compounds and their use as anti-viral agents |
| 05/29/2007 | US7223789 Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 05/29/2007 | US7223788 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders |
| 05/29/2007 | US7223787 Reducing permissiveness of human cells to replication of certain pathogenic human viruses by treating the cells with a selective inhibitor of prenylation of a host cell protein; may have use in treating infections by HCV and Flaviviridae viruses |
| 05/29/2007 | US7223786 For example, 5-Chloro-1H-indole-2-carboxylic acid (3-hydroxynaphthalen-2-yl)amide; glycogen phosphorylase inhibitors useful in treating, preventing or slowing progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and hyperglycemia |
| 05/29/2007 | US7223785 Viral polymerase inhibitors |
| 05/29/2007 | US7223784 Compounds for the modulation of the glycolysis enzyme and/or transaminase complex |
| 05/29/2007 | US7223783 Indolinone derivatives |
| 05/29/2007 | US7223782 Pyrazole-amides and -sulfonamides |
| 05/29/2007 | US7223781 Immunomoderators; autoimmune disease; drug, cosmetics; antiinflammatory agnets |
| 05/29/2007 | US7223780 Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| 05/29/2007 | US7223779 Azasugar derivative and drug containing the same as the active ingredient |
| 05/29/2007 | US7223778 5-substituted-2-arylpyridines |
| 05/29/2007 | US7223777 Such as 1-(2-thien-2'-yl- 2-oxoethyl)-3-((3-phenylmethyl) pyrazol-5-yl)pyridinium bromide for treating diseases caused by the accumulation of AGE (Advanced Glycation Endproducts); antidiabetic/ antiaging agents |
| 05/29/2007 | US7223776 Compounds with anti-bacterial activity |
| 05/29/2007 | US7223775 Stabilized ascorbic acid derivatives |
| 05/29/2007 | US7223774 Benzamide 2-hydroxy-3-diaminoalkanes |
| 05/29/2007 | US7223773 Having antibacterial effect on gram-positive bacteria, gram-negative bacteria or anaerobic bacteria |
| 05/29/2007 | US7223772 Cyclooxygenase-2 inhibitors (COX-2); 4-[2-(3-fluoro-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide for example; fever, pain, inflammation, neurodegenerative disorders, oral diseases, influenza, arthritis, allergies |
| 05/29/2007 | US7223771 Inhibit the secretion of gastric acid; methyl 2,3-dimethyl-9-(2-ethyl-6-methyl-phenyl)-7H-8,9-dihydro-pyrano[2,3-c]-imidazo[1,2-a]pyridine-6-carboxylate for example; gastrointestinal inflammatory diseases such as gastric ulcers; high selectivity of action, side effect reduction, good enteral activity |
| 05/29/2007 | US7223770 Tocopherol-modified therapeutic drug compounds |
| 05/29/2007 | US7223768 Fused ring heterocycles as potassium channel modulators |
| 05/29/2007 | US7223767 Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists |
| 05/29/2007 | US7223766 Bi-cyclic pyrimidine inhibitors of TGFβ |
| 05/29/2007 | US7223765 3-[4-(3,4-Dichlorophenyl)piperazin-1-yl]-1-(2,3-dihydro-1H-indol-1-yl)propan-1-one or salts for example; psychological disorders such as schizophrenia, generalised anxiety disorder, panic disorder, and obsessive compulsive disorder; high affinity for dopamine D4 receptors |
| 05/29/2007 | US7223764 Antilipemic agents; anticholesterol agents |
| 05/29/2007 | US7223763 Substituted sulfonamides and ureas useful for inhibiting kinase activity |
| 05/29/2007 | US7223761 Salts and polymorphs of a potent antidiabetic compound |
| 05/29/2007 | US7223760 Substituted triazole compounds |
| 05/29/2007 | US7223759 N-(4-(2,2-difluoro-benzo(1,3)dioxol-5-ylcarbamoyl)-3-hydroxy-phenyl)-4,6-Bis-((3R,5S)-3,5-diamino-piperidin-1-yl)-(1,3,5)triazine-2-amine for example; Gram-positive and Gram-negative strains; retains potency against common antibiotic resistant strains |
| 05/29/2007 | US7223758 Such as (3S)-2-[3-[(phenylacetyl)amino]-1-oxopropyl]-N-[cyano(3-phenoxyphenyl)methyl]hexahydro-3-pyridazinecarboxamide; for treatment of osteoporosis, hypercalcaemia, osteoporosis, gingival disease, arthritis, Paget's disease, and bone cancer |
| 05/29/2007 | US7223757 Such as (S)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{6-[4-(2-methoxy-ethyl)-piperazin-1-yl]-4-methyl-1H-benzimidazol-2-yl}-1H-pyridin-2-one bis hydrochloride; anticancer agents; antiproliferative agents |
| 05/29/2007 | US7223756 Treatment of autoimmune diseases, transplant rejection and rheumatoid arthritis with a quinazoline 4-substituted by a methylenedioxyphenyl group linked to the ring by an ether, methyl, sulfide, sulfoxide or sulfone, e.g., 6-methoxy-4-(2,3-methylenedioxyphenoxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline, |
| 05/29/2007 | US7223755 Such as (2S,5S)-5-benzyl-6-hydroxy-2-(2-methylpropyl)-3-morpholinone, which has calpain inhibitory activity; for treating cataract or retinal ischemic disorder |
| 05/29/2007 | US7223754 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders |
| 05/29/2007 | US7223753 Diazabicyclic biaryl derivatives |
| 05/29/2007 | US7223752 Biphenyl vasopressin agonists |
| 05/29/2007 | US7223751 Sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same |
| 05/29/2007 | US7223750 Therapy for disease caused by nicotinic receptors; cognition activatrors; central nervous system disorders |
| 05/29/2007 | US7223749 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 05/29/2007 | US7223748 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| 05/29/2007 | US7223747 Halocombstatins and methods of synthesis thereof |
| 05/29/2007 | US7223746 Ocular hypotensive agents; asthma, dysmenorrheal, osteoporosis, constipation, renal/sexual disorders, baldness, diabetes, cancer, immune disorders, acute myocardial infarction, vascular thrombosis, hypertension, pulmonary hypertension, ischemic heart disease, congestive heart failure, and angina |
| 05/29/2007 | US7223745 Proteasome inhibitors and methods of using the same |
| 05/29/2007 | US7223744 Such as P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-)tetraphosphate, tetra-(alkali metal) salts; P2Y receptor agonist with enhanced resistance to extracellular hydrolysis |
| 05/29/2007 | US7223741 nucleic acids containing unmethylated cytosine-guanine (CpG) dinucleotides activate lymphocytes in a subject and redirect a subject's immune response from a Th2 to a Th1 |
| 05/29/2007 | US7223738 Inhibitors of Akt activity |
| 05/29/2007 | US7223737 topical compositions do not contain active ingredients for treating ocular disorders other than dry eye |
| 05/29/2007 | US7223736 Composition for the prevention and treatment of cachexia |
| 05/29/2007 | US7223735 Abuse resistant lysine amphetamine compounds |
| 05/29/2007 | US7223728 Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes |
| 05/29/2007 | US7223600 cell is contacted with a photosentistising agent, cell is irradiated with light to activate photosentisitising agent, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination |
| 05/29/2007 | US7223593 Anticancer agents; gene coding immunomoderator cytokine protein |
| 05/29/2007 | US7223591 Strain of lactic acid bacterium and edible compositions, drugs and veterinary products containing it |
| 05/29/2007 | US7223563 Nucleic acids; diagnosing and treating hypophosphatemic disorders; diagnosing tumor induced osteomalacia |
| 05/29/2007 | US7223554 Inhibitors of proteasomal activity for stimulating hair growth |
| 05/29/2007 | US7223542 Diagnosing cancer via determining concentration of marker polypeptides; genetic vaccines; antiproliferative/antitumor agents |
| 05/29/2007 | US7223450 Chiral compounds |
| 05/29/2007 | US7223440 Residual solvent extraction method and microparticles produced thereby |
| 05/29/2007 | US7223424 Comprising aliquot of the herb Herba Epimedii and aliquot of three supplemental herbs selected from Fructus Rosae Laevigatae, Fructus Rubi, Fructus Psoralea, Radix Morindae Officinalis, Fructus Schisandrac Chinensis, and others |
| 05/29/2007 | US7223419 Stabilizing a high concentrate drug content in water, by dissolving the drug and a polyetheramide copolymer in solvent, forming water in oil emulsion, volatilizing, desolventizing, supersonic treatment and ultrafiltration |
| 05/29/2007 | US7223417 Nutrient formulations |
| 05/29/2007 | US7223416 Topical composition |
| 05/29/2007 | US7223413 Composition of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; heart can be better protected during arrest and recovery by using the potassium channel opener adenosine and the local anaesthetic lignocaine |
| 05/29/2007 | US7223397 Administering an agent which upregulates the expression of a cellular target; administering a dose of an immunotoxin directed against the upregulated cellular target |
| 05/29/2007 | US7223394 Human antibodies that bind human TNFα |
| 05/29/2007 | US7223387 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
| 05/29/2007 | US7223386 comprising silicone matrix, a hydrophilic carrier, and at least one active agent comprising proteins, particularly enzymes such as hydrolases and glucose oxidase for enzymatic debridement, clotting formation and clot removal and wound healing |
| 05/29/2007 | US7223383 Stabilized sunscreen composition having a particulate inorganic sunscreen |
| 05/29/2007 | US7223381 Pressurised metered dose inhalers (MDI) |
| 05/29/2007 | CA2569162A1 Amphiphilic copolymer compositions |
| 05/29/2007 | CA2498415C Solid formulations comprising an indolinone compound |
| 05/29/2007 | CA2401731C Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| 05/29/2007 | CA2401718C Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins |
| 05/29/2007 | CA2340052C Pharmaceutical compositions containing lipase inhibitors and chitosan |
| 05/29/2007 | CA2338324C Stabilized carvedilol injection solution |
| 05/29/2007 | CA2336732C Topical plaster with non-steroidal antirheumatic agents with an acid group |
| 05/29/2007 | CA2333375C Sublingual buccal effervescent |
| 05/29/2007 | CA2313504C Folic acid in solid dosage forms |
| 05/29/2007 | CA2275420C Stable liquid mineral ascorbate compositions and methods of manufacture and use |
| 05/29/2007 | CA2258679C Solid solution of an antifungal agent with enhanced bioavailability |
| 05/29/2007 | CA2251297C Oral preparations comprising s-(3-hydroxypropyl)-l-cysteine |
| 05/29/2007 | CA2247467C Use of piperine as a bioavailability enhancer |
| 05/29/2007 | CA2236998C Tissue-specific and target rna-specific ribozymes |
| 05/29/2007 | CA2214565C New cryptophycins from synthesis |
| 05/29/2007 | CA2213989C External preparation for topical administration |
| 05/29/2007 | CA2212109C Method and compositions for topical application of tocotrienol to the skin |
| 05/29/2007 | CA2208754C Bioabsorbable oxidized cellulose composite material for prevention of postsurgical adhesions |
| 05/29/2007 | CA2206265C Process for reducing rna concentration in a mixture of biological material using diatomaceous earth |